- Home
- CIVB vs RNAC Comparison
CIVB vs RNAC Comparison
Compare CIVB & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIVB
- RNAC
- Stock Information
- Founded
- CIVB 1884
- RNAC 2007
- Country
- CIVB United States
- RNAC United States
- Employees
- CIVB N/A
- RNAC N/A
- Industry
- CIVB Major Banks
- RNAC Biotechnology: Pharmaceutical Preparations
- Sector
- CIVB Finance
- RNAC Health Care
- Exchange
- CIVB Nasdaq
- RNAC Nasdaq
- Market Cap
- CIVB 358.0M
- RNAC 422.4M
- IPO Year
- CIVB N/A
- RNAC 2016
- Fundamental
- Price
- CIVB $21.33
- RNAC $19.02
- Analyst Decision
- CIVB Buy
- RNAC Strong Buy
- Analyst Count
- CIVB 4
- RNAC 8
- Target Price
- CIVB $21.67
- RNAC $41.67
- AVG Volume (30 Days)
- CIVB 63.6K
- RNAC 161.9K
- Earning Date
- CIVB 02-06-2025
- RNAC 11-07-2024
- Dividend Yield
- CIVB 3.00%
- RNAC N/A
- EPS Growth
- CIVB N/A
- RNAC N/A
- EPS
- CIVB 2.00
- RNAC N/A
- Revenue
- CIVB $146,565,000.00
- RNAC $47,938,000.00
- Revenue This Year
- CIVB N/A
- RNAC $56.06
- Revenue Next Year
- CIVB $6.26
- RNAC N/A
- P/E Ratio
- CIVB $10.68
- RNAC N/A
- Revenue Growth
- CIVB N/A
- RNAC N/A
- 52 Week Low
- CIVB $13.60
- RNAC $11.67
- 52 Week High
- CIVB $23.70
- RNAC $41.87
- Technical
- Relative Strength Index (RSI)
- CIVB 42.29
- RNAC 47.25
- Support Level
- CIVB $20.66
- RNAC $16.70
- Resistance Level
- CIVB $22.95
- RNAC $19.98
- Average True Range (ATR)
- CIVB 0.63
- RNAC 2.39
- MACD
- CIVB -0.31
- RNAC -0.37
- Stochastic Oscillator
- CIVB 26.27
- RNAC 23.67
About CIVB Civista Bancshares Inc.
Civista Bancshares Inc is a financial holding company. Operating through its subsidiary, it engages in the business of community banking. Its business activity involves collecting customer deposits, making loans, purchasing securities, and offering trust services to its clients. The company's loan portfolio includes commercial and agriculture, commercial real estate-owner occupied, commercial real estate non-owner occupied, residential real estate, real estate construction, and consumer loans. Majority of its revenues are derived from the interest and fees gained on loans.
About RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.